Arvinas (ARVN) Stock Forecast, Price & News

15 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 3 hold ratings and 12 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ARVN shares.
View ARVN analyst ratings or view top-rated stocks.

15 analysts have issued 12-month price targets for Arvinas' shares. Their ARVN share price forecasts range from $27.00 to $95.00. On average, they expect the company's stock price to reach $64.07 in the next twelve months. This suggests a possible upside of 211.6% from the stock's current price.
View analysts price targets for ARVN or view top-rated stocks among Wall Street analysts.

Arvinas' stock was trading at $34.21 at the beginning of the year. Since then, ARVN shares have decreased by 39.9% and is now trading at $20.56.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our ARVN earnings forecast.

Arvinas, Inc. (NASDAQ:ARVN) released its earnings results on Tuesday, August, 8th. The company reported ($1.25) earnings per share for the quarter, topping analysts' consensus estimates of ($1.65) by $0.40. The business earned $54.50 million during the quarter, compared to analyst estimates of $30.94 million. Arvinas had a negative trailing twelve-month return on equity of 55.09% and a negative net margin of 191.63%. The company's revenue was up 74.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.32) earnings per share.

ETFs with the largest weight of Arvinas (NASDAQ:ARVN) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH), Fidelity Disruptive Medicine ETF (FMED), ALPS Medical Breakthroughs ETF (SBIO) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE) and

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an initial public offering on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray acted as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.17%), JPMorgan Chase & Co. (3.74%), ArrowMark Colorado Holdings LLC (3.37%), State Street Corp (2.09%), Geode Capital Management LLC (1.86%) and Candriam S.C.A. (0.88%). Insiders that own company stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends.

Shares of ARVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $20.56.

Arvinas (NASDAQ:ARVN) has a market capitalization of $1.10 billion and generates $131.40 million in revenue each year. The company earns $-282,500,000.00 in net income (profit) each year or ($5.59) on an earnings per share basis.

The company employs 415 workers across the globe.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The official website for the company is www.arvinas.com. The company can be reached via phone at (203) 535-1456 or via email at ir@arvinas.com.